Why is GSK closing its Dresden vaccine factory, and which vaccines are produced there?

GSK is closing its Dresden vaccine factory in summer 2027 due to 'decreasing demand for traditional egg-based flu vaccines', resulting in excess manufacturing capacity; the facility produces flu and hepatitis vaccines, as confirmed by GSK's website.

What is GSK's stated rationale for choosing the Ste-Foy, Canada site over Dresden for consolidated flu vaccine production?

GSK selected the Ste-Foy, Canada site because it 'can fully match anticipated future demand in a sustainable and competitive way', following a review of the viability of its two flu vaccine manufacturing sites in Dresden and Ste-Foy.

GSK to Shut Vaccine Factory in Germany, Putting 641 Jobs at Risk

Sep 11, 2026

GSK plans to close its Dresden vaccine factory by summer 2027, risking 641 jobs as it consolidates production in Canada due to declining demand for traditional flu vaccines. The company also advances its mRNA influenza vaccine candidate to late-stage trials.

reuters

2026-01-27

Jan. 27 Business Watch: Vioneo moves project to China; GSK to buy Rapt Therapeutics for $2.2 billion

2026-09-11

GSK to Shut Vaccine Factory in Germany, Putting 641 Jobs at Risk

GSK to Shut Vaccine Factory in Germany, Putting 641 Jobs at Risk

FAQ